
October 1, 2021
Carolina Research Leads to Effective Experimental Pill to Treat COVID-19
University of North Carolina at Chapel Hill research set the stage to seek emergency authorization of the first oral antiviral drug to treat COVID-19, a pill developed by the pharmaceutical companies Merck and Ridgeback Biotherapeutics. William Fischer, MD, at the UNC School of Medicine led pivotal clinical trials on the drug molnupiravir.